David Ternant

4.5k citations

93 papers · 2.8k indexed · h-index 29

Impact in

Immunology top 2%
- Biosimilars and Bioanalytical Methods
- Immunodeficiency and Autoimmune Disorders
Genetics top 2%
- Inflammatory Bowel Disease
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Genetics 24
- Chronic Lymphocytic Leukemia Research 21
- Inflammatory Bowel Disease 11
Transplantation 6

Co-authors: Gilles Paintaud (70 shared papers)Denis Mulleman (24 shared papers)Hervé Watier (12 shared papers)Philippe Goupille (13 shared papers)Charlotte Magdelaine–Beuzelin (3 shared papers)Hervé Watier (6 shared papers)Danielle Degenne (5 shared papers)Émilie Ducourau (7 shared papers)
Journals: British Journal of Clinical Pharmacology (14 papers)Clinical Pharmacokinetics (13 papers)Therapeutic Drug Monitoring (9 papers)mAbs (4 papers)Scientific Reports (3 papers)
Partner nations: France United States Belgium

In The Last Decade

David Ternant

91 papers receiving 2.7k citations

Peers

Countries citing papers authored by David Ternant

Since Specialization

Citations

This map shows the geographic impact of David Ternant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Ternant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Ternant more than expected).

Fields of papers citing papers by David Ternant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Ternant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Ternant. The network helps show where David Ternant may publish in the future.

Co-authors

The 25 scholars most cited alongside David Ternant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Ternant Line = papers co-authored together David Ternant links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 93 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial Gastroenterology ·Gert Van Assche, Charlotte Magdelaine–Beuzelin, Geert D’Haens, Filip Baert, Maja Noman, Séverine Vermeire, David Ternant, Hervé Watier, Gilles Paintaud, Paul Rutgeerts	2008	381
2	Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients Therapeutic Drug Monitoring ·David Ternant, Alexandre Aubourg, Charlotte Magdelaine–Beuzelin, Danielle Degenne, Hervé Watier, Laurence Picon, Gilles Paintaud	2008	151
3	Behavior and serotonergic disorders in rats exposed prenatally to valproate: A model for autism Neuroscience Letters ·Diane Dufour‐Rainfray, Patrick Vourc’h, Anne‐Marie Le Guisquet, Lucette Garreau, David Ternant, Sylvie Bodard, Emilie Jaumain, Zuhal Gulhan, Catherine Belzung, Christian Andrés, Sylvie Chalon, Denis Guilloteau	2009	128
4	Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases Arthritis Research & Therapy ·Émilie Ducourau, Denis Mulleman, Gilles Paintaud, Delphine Miow Lin, Francine Lauféron, David Ternant, Hervé Watier, Philippe Goupille	2011	127
5	Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20 Blood ·David Daydé, David Ternant, Marc Ohresser, Stéphanie Lerondel, Sabrina Pesnel, Hervé Watier, Alain Le Pape, P. Bardos, Gilles Paintaud, Guillaume Cartron	2008	91
6	Pharmacokinetics and concentration–effect relationships of therapeutic monoclonal antibodies and fusion proteins Expert Opinion on Biological Therapy ·David Ternant, Gilles Paintaud	2005	89
7	An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Infliximab Therapeutic Drug Monitoring ·David Ternant, Denis Mulleman, Danielle Degenne, S. Willot, Jean-Maurice Guillaumin, Hervé Watier, Philippe Goupille, Gilles Paintaud	2006	86
8	Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis Clinical Pharmacokinetics ·David Ternant, Théodora Bejan‐Angoulvant, Christophe Passot, Denis Mulleman, Gilles Paintaud	2015	84
9	Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients Clinical Cancer Research ·Nicolas Azzopardi, Thierry Lecomte, David Ternant, Michelle Boisdron-Celle, Friedrich Piller, Alain Morel, Valérie Gouilleux‐Gruart, Céline Vignault-Desvignes, Hervé Watier, Érick Gamelin, Gilles Paintaud	2011	80
10	Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis British Journal of Clinical Pharmacology ·David Ternant, Émilie Ducourau, P. Fuzibet, Céline Vignault, Hervé Watier, Thierry Lequerré, Xavier Le Loët, Olivier Vittecoq, Philippe Goupille, Denis Mulleman, Gilles Paintaud	2014	72
11	Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis British Journal of Clinical Pharmacology ·David Ternant, Émilie Ducourau, Aleth Perdriger, Anca Corondan, Benoît Le Goff, Valérie Devauchelle‐Pensec, Elisabeth Solau‐Gervais, Hervé Watier, Philippe Goupille, Gilles Paintaud, Denis Mulleman	2013	70
12	Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report Blood ·Mira Tout, Olivier Casasnovas, Michel Meignan, T. Lamy, Franck Morschhauser, Gilles Salles, Emmanuel Gyan, Corinne Haïoun, Mélanie Mercier, Pierre Feugier, Sami Boussetta, Gilles Paintaud, David Ternant, Guillaume Cartron	2017	64
13	Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule mAbs ·Philippe Gatault, Guillaume Brachet, David Ternant, Danielle Degenne, Guillaume Récipon, Christelle Barbet, Emmanuel Gyan, Valérie Gouilleux‐Gruart, Cécile Bordes, Alexandra Farrell, Jean‐Michel Halimi, Hervé Watier	2015	61
14	The underlying inflammatory chronic disease influences infliximab pharmacokinetics mAbs ·Christophe Passot, Denis Mulleman, Théodora Bejan‐Angoulvant, Alexandre Aubourg, S. Willot, Thierry Lecomte, Laurence Picon, Philippe Goupille, Gilles Paintaud, David Ternant	2016	54
15	An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab Therapeutic Drug Monitoring ·Nicolas Cézé, David Ternant, (unknown), Danielle Degenne, Nicolas Azzopardi, Étienne Dorval, Hervé Watier, Thierry Lecomte, Gilles Paintaud	2009	53
16	Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis Therapeutic Drug Monitoring ·Denis Mulleman, D. Chu Miow Lin, Émilie Ducourau, Patrick Emond, David Ternant, Charlotte Magdelaine–Beuzelin, Jean‐Pierre Valat, Gilles Paintaud, Philippe Goupille	2010	52
17	Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease Clinical Pharmacokinetics ·David Ternant, Zahir Berkane, Laurence Picon, Valérie Gouilleux‐Gruart, Jean–Frédéric Colombel, Matthieu Allez, Édouard Louis, Gilles Paintaud	2014	52
18	IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding The Journal of Immunology ·David Ternant, Christophe Arnoult, Martine Pugnière, Christine Dhommée, Daniel Drocourt, Éric Pérouzel, Christophe Passot, Nadine Baroukh, Denis Mulleman, Gérard Tiraby, Hervé Watier, Gilles Paintaud, Valérie Gouilleux‐Gruart	2015	51
19	Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients Clinical Pharmacokinetics ·Morgane Caulet, Thierry Lecomte, Olivier Bouché, Jérôme Rollin, Valérie Gouilleux‐Gruart, Nicolas Azzopardi, Julie Léger, Christophe Borg, Jean‐Yves Douillard, Sylvain Manfrédi, Denis Smith, Olivier Capitain, Aurélie Ferru, Driffa Moussata, Eric Terrebone, Gilles Paintaud, David Ternant	2016	49
20	Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases Clinical Rheumatology ·Mario Ojeda‐Uribe, Naji Afif, Étienne Dahan, L. Sparsa, Celine Haby, Jean Sibilia, David Ternant, M. Ardizzone	2013	49

About David Ternant

David Ternant is a scholar working on Genetics, Transplantation, Radiology, Nuclear Medicine and Imaging, Rheumatology and Immunology, having authored 93 papers that have together received 2.8k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (32 papers), Chronic Lymphocytic Leukemia Research (21 papers), Systemic Lupus Erythematosus Research (16 papers), Rheumatoid Arthritis Research and Therapies (15 papers), Biosimilars and Bioanalytical Methods (12 papers), Inflammatory Bowel Disease (11 papers), Colorectal Cancer Treatments and Studies (9 papers) and Immunodeficiency and Autoimmune Disorders (9 papers). The work is most often cited by research in Immunology (1.0k citations), Genetics (462 citations), Radiology, Nuclear Medicine and Imaging (816 citations), Rheumatology (470 citations) and Genetics (833 citations). David Ternant has collaborated with scholars based in France, United States and Belgium. Frequent co-authors include Gilles Paintaud, Denis Mulleman, Hervé Watier, Philippe Goupille, Charlotte Magdelaine–Beuzelin, Hervé Watier, Danielle Degenne, Émilie Ducourau, Théodora Bejan‐Angoulvant and Christophe Passot. Their work appears in journals such as British Journal of Clinical Pharmacology, Clinical Pharmacokinetics, Therapeutic Drug Monitoring, mAbs and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact